The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Preceding infections, immune factors, and outcome in Guillain–Barré syndrome
Abstract
OBJECTIVE: To test the hypothesis that different preceding infections influence the neurophysiologic classification and clinical features of Guillain-Barré syndrome (GBS). METHODS: We tested pretreatment sera, 7 +/- 3 (mean +/- SD) days from onset, from 229 patients with GBS in a multicenter trial of plasma exchange and immunoglobulin, for serological markers of infection, adhesion molecules, and cytokine receptors, and compared these with neurophysiologic and clinical features. RESULTS: Recent infection by Campylobacter jejuni was found in 53 patients (23%), cytomegalovirus in 19 (8%), and Epstein-Barr virus in four (2%). Patients with C. jejuni infection were more likely than others to have neurophysiologic criteria of axonal neuropathy or inexcitable nerves, antiganglioside GM(1) antibodies, pure motor GBS, lower CSF protein, and worse outcome. Patients with cytomegalovirus infection were younger and more likely than others to have raised serum concentrations of molecules important in T lymphocyte activation and migration, soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble leukocyte selectin, and soluble interleukin-2 receptor (sIL-2R). Concentrations of sICAM-1 and soluble tumor necrosis factor receptor were higher in patients with inexcitable nerves than those with demyelinating neurophysiology. Logistic regression analysis showed death or inability to walk unaided at 48 weeks were associated with diarrhea, inexcitable nerves, severe arm weakness, age over 50, raised sIL-2R concentration and absence of immunoglobulin (Ig) M antiganglioside GM(1) antibodies. CONCLUSIONS: Subtypes of GBS defined by preceding infections were only approximately associated with different patterns of clinical, neurophysiologic, and immunologic features. A single infectious agent caused more than one type of pathology in GBS, implying interaction with additional host factors. Most patients had no identified infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcome
Hadden, R. D. M., Cornblath, D. R., Hughes, R. A. C., Zielasek, J., Hartung, H. ‐., Toyka, K. V., Swan, A. V., & The Plasma Exchange/Sandoglobulin Guillain‐Barré Syndrome Trial Group (1998) · Annals of Neurology · doi:10.1002/ana.410440512 · Cited by 942
Self-citationThe spectrum of antecedent infections in Guillain-Barré syndrome: A case-control study
Jacobs, B. C., Rothbarth, P. H., van der Meché, F. G. A., Herbrink, P., Schmitz, P. I. M., de Klerk, M. A., & van Doorn, P. A. (1998) · Neurology · doi:10.1212/wnl.51.4.1110 · Cited by 826
Ho, T. W., Mishu, B., Li, C. Y., Gao, C. Y., Cornblath, D. R., Griffin, J. W., Asbury, A. K., Blaser, M. J., & McKhann, G. M. (1995) · Brain · doi:10.1093/brain/118.3.597 · Cited by 764
Self-citationCampylobacter jejuni Infection and Guillain–Barré Syndrome
Rees, J. H., Soudain, S. E., Gregson, N. A., & Hughes, R. A. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511233332102 · Cited by 753
Self-citation(1997) · The Lancet · doi:10.1016/s0140-6736(96)09095-2 · Cited by 733
(1997) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(97)80059-4 · Cited by 610
Six widespread bacterial clones among Escherichia coli K1 isolates
Achtman, M., Mercer, A., Kusecek, B., Pohl, A., Heuzenroeder, M., Aaronson, W., Sutton, A., & Silver, R. P. (1983) · Infection and Immunity · doi:10.1128/iai.39.1.315-335.1983 · Cited by 447
Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barr� syndrome
Ho, T. W., Willison, H. J., Nachamkin, I., Li, C. Y., Veitch, J., Ung, H., Wang, G. R., Liu, R. C., Cornblath, D. R., Asbury, A. K., et al. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199902)45:2<168::aid-ana6>3.0.co;2-6 · Cited by 329
Self-citationCampylobacter jejuni infections and anti‐GM1 antibodies in guillain‐barré syndrome
Jacobs, B. C., van Doorn, P. A., Tio‐Gillen, A. P., Visser, L. H., van der Meché, F. G. A., Schmitz, P. I. M., Herbrink, P., & Hooijkaas, H. (1996) · Annals of Neurology · doi:10.1002/ana.410400209 · Cited by 314
A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value.
Winer, J. B., Hughes, R. A., & Osmond, C. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.5.605 · Cited by 297
Self-citation
Cited by
Hughes, R. A., & Cornblath, D. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67665-9 · Cited by 1,676
Self-citationWillison, H. J., Jacobs, B. C., & van Doorn, P. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00339-1 · Cited by 1,609
Yuki, N., & Hartung, H.-P. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1114525 · Cited by 1,260
Self-citationGuillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis
van den Berg, B., Walgaard, C., Drenthen, J., Fokke, C., Jacobs, B. C., & van Doorn, P. A. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.121 · Cited by 1,101
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
van Doorn, P. A., Ruts, L., & Jacobs, B. C. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70215-1 · Cited by 828
Metadata
- Authors
- Hadden, R. D. M., Karch, H., Hartung, H.-P., Zielasek, J., Weissbrich, B., Schubert, J., Weishaupt, A., Cornblath, D. R., Swan, A. V., Hughes, R. A. C., Toyka, K. V., & the Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group*
- Venue
- Neurology
- Published
- 2001-03-27
- Volume
- 56
- Issue
- 6
- Pages
- 758-765
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1986245753
- Cited by
- 375
- References
- 33
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preceding infections, immune factors, and outcome in Guillain–Barré syndrome. https://app.cochat.ai/papers/10.1212/wnl.56.6.758
- The paper
- Hadden, R. D. M., Karch, H., Hartung, H.-P., Zielasek, J., Weissbrich, B., Schubert, J., Weishaupt, A., Cornblath, D. R., Swan, A. V., Hughes, R. A. C., Toyka, K. V., & the Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group*. (2001). Preceding infections, immune factors, and outcome in Guillain–Barré syndrome. Neurology. https://doi.org/10.1212/wnl.56.6.758
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.